Inhibitor Therapeutics (INTI) Cash & Equivalents (2012 - 2026)
Inhibitor Therapeutics (INTI) reported Cash & Equivalents of $515,758 for Q2 2026, down 86.2% from $3.74 million a year earlier and down 60.0% from the prior quarter.
Inhibitor Therapeutics (INTI) Cash & Equivalents (2012 - 2026) Analysis & Trends
At the end of FY2025, Inhibitor Therapeutics posted Cash & Equivalents of $2.38 million, down 57.6% from FY2024.
- Cash & Equivalents has declined for three consecutive years, though with a five-year compound annual growth rate of 99.6% (FY2020 to FY2025).
- By year, Cash & Equivalents came in at $5.61 million in FY2024 (-36.6%), $8.84 million in FY2023 (-26.0%), $11.95 million in FY2022 and $30,626 in FY2021 (-59.2%).
- The Q2 2026 figure ranks as the lowest quarterly Cash & Equivalents since Q3 2022.
- Year over year, Cash & Equivalents has now declined in each of the last 11 quarters, with an average decline of 53.5% over the last eight quarters.
- The high point for year-over-year Cash & Equivalents in five years was Q3 2021 (growth of 172.4%); the low point was Q2 2026 (a decline of 86.2%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $1.29 million (Q1 2026), $2.38 million (Q4 2025) and $3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Inhibitor Therapeutics | 17.38 Mn | 17.38 Mn | - | 515,758.00 |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 515,758.00 |
| Mar 31, 2026 | 1.29 Mn |
| Dec 31, 2025 | 2.38 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 3.74 Mn |
| Mar 31, 2025 | 4.32 Mn |
| Dec 31, 2024 | 5.61 Mn |
| Sep 30, 2024 | 6.40 Mn |
| Jun 30, 2024 | 7.10 Mn |
| Mar 31, 2024 | 7.70 Mn |
| Dec 31, 2023 | 8.84 Mn |
| Sep 30, 2023 | 9.54 Mn |
| Jun 30, 2023 | 10.10 Mn |
| Mar 31, 2023 | 10.78 Mn |
| Dec 31, 2022 | 11.95 Mn |
| Sep 30, 2022 | 53,058.00 |
| Jun 30, 2022 | 24,945.00 |
| Mar 31, 2022 | 36,438.00 |
| Dec 31, 2021 | 30,626.00 |
| Sep 30, 2021 | 100,000.00 |
Inhibitor Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=INTI&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "INTI", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=INTI&period=max&api_key=YOUR_API_KEY");
const data = await res.json();